Royalty Pharma plc (RPRX)

28.16 +0.27 (+0.97%) At close: 04:00PM EDT

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO	N/A	N/A	1965
Mr. Terrance P. Coyne	Executive VP & CFO	4.35M	N/A	N/A
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer	4.35M	N/A	1960
Mr. Christopher Hite	Vice Chairman & Executive VP	4.35M	N/A	1967
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive VP and Head of Research & Investments	4.35M	N/A	N/A
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel	N/A	N/A	N/A
Mr. Ashwin Pai M.D.	Executive Vice President of Investments	N/A	N/A	N/A
Ms. Kristin Stafford	Senior VP & Chief Accounting Officer	N/A	N/A	1983
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer	N/A	N/A	N/A
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer	3.4M	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Corporate governance

Royalty Pharma plc’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 5; Board: 5; Shareholder rights: 6; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.